XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.4

OPERATING SEGMENT (Tables)

12 Months Ended

Dec. 31, 2025

OPERATING SEGMENT

Schedule of financial data for the one reportable segment

​

​	​	​	​	​	​	​
​	​ ​ ​	Year Ended December 31,
​	​ ​ ​	2025		​ ​ ​	2024
Research and development:		​	​		​	​
Phase 2 study in WM	​	$	1,308,000	​	$	7,422,000
Phase 1 study in pediatric tumors	​		1,345,000	​		3,040,000
Phase 1 study in Triple Negative Breast Cancer	​	​	933,000	​	​	—
Manufacturing and related costs	​		4,220,000	​		10,582,000
Pre-clinical projects costs	​		823,000	​		228,000
General research and development costs	​		2,870,000	​		4,864,000
General and administrative	​		11,481,000	​		25,641,000
Other segment items	​		(1,189,000)	​		(7,196,000)
Segment and consolidated net loss	​	$	21,791,000	​	$	44,581,000

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration